title: Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.
abstract: The incidence of melanoma has increased for decades, and while surgical treatment of early stage disease is often curative, metastatic disease continues to carry a significantly less promising outlook with high associated health burden and economic cost. An expanding number of dermatologists are playing a key role in coordinating the care of patients with melanoma, including in an increasingly important role among multidisciplinary melanoma clinics, many of which are anchored in dermatology departments. Advances in the understanding of the genetic and immunoregulatory aspects of melanoma development and progression have yielded a wave of novel therapeutics that has made significant impact on the approach to patients with metastatic disease. Frequently updated management guidelines and unfamiliarity with approved adjuvant treatment options, including interferon, clinical trials, or radiation therapy, can pose a challenge for dermatologists seeking to effectively coordinate the care of and establish proper expectations for patients with stage III disease. Moreover, greater awareness of treatment modalities for in-transit disease may allow dermatologists to play a more active role in the treatment of these patients and to expand their ability to explain and coordinate options, such as limb perfusion or infusion. Part I of this continuing medical education article will use clinical scenarios to outline the current management options for patients with stage III melanoma, including both adjuvant treatment options for resected stage III disease and primary treatment options for in-transit metastases. Part II of this series will address stage IV disease.
authors.affiliation: Department of Dermatology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan, USA. matfox@med.umich.edu
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Fox
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Lao
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Schwartz
authors.forename: Marcus L
authors.initials: ML
authors.lastname: Frohm
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Johnson
mesh_terms: D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D009367:Neoplasm Staging; D011159:Population Surveillance; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*
chemical_list: D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins